Please Scroll Down to See Forums Below
Anybody use GHRP2?
- Thread starter The Man Child
- Start date
angelsfire
New member
There are over-the-counter products that do contain real hGH, the FDA allows a certain (very tiny) amount of GH to be used in otc supplements. However, the amount they are allowed to include is so ridiculously small it might as well not be there. the GHRP-2 doesn't contain any GH, like the abstract said it's a secretagogue (releases gh). Yes gh (or the GHRP-2 product) can and will make you grow taller, but only if it's used before you're natural growth is over. What happens is the epiphyseal plates in your long bones fuse, preventing further vertical growth. What causes them to fuse is estrogen, this is why women stop growing sooner than men (more estrogen) and also why aromatizing drugs are contraindicated for anyone below the age of 21. By age 21 most males have produced enough estrogen in their lifetime to have fused all of their long bones. Not all of your bones loose capacity for growth however, like your hands and feet, and jawbone, that's why some bodybuilders get the frankenstein look.
Justtryingnot2getfat
New member
first of all - its not GH. GHRP=growth hormone-releasing peptide. It is also made by Penlabs American Peptide Company, europeptides, Kaken and Atrix Laboratories among others but is mondo expensive. There are a buch of supps that claim to be this but are mostly composed of arginine and otehr aminos not actual peptides, like the GH sprays. Apparently Asians seem to produce GHRP2. while the US companies make GHRP6 - why, cause smith kline owns it (6).
GHRP was discovered by Bowers (Tulane University) 20 years ago. They act on different receptors than GH releasing hormone (GHRH) and is active orally - tho bioavailability varies from less than 1% to 50% dep on admin.
Basically teh stuff works - saw somewhere that it upped GH production by 5x in rats. Looks like snorting it might be best tho - IP's stuff is sublingual, still good IMHO.
What I would like to see is a study of the effects of GHRP and GHB (to induce REM sleep) together!!!!
Authors
Frieboes RM, Murck H, Antonijevic IA, Steiger A.
Title
Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: Role of routes of administration
Source
Journal of Neuroendocrinology. 11(6):473-478, 1999 Jun.
Author Keywords
Growth hormone, Growth hormone-releasing peptides, Corticotropins, Clinical neuroendocrinology, Sleep.
KeyWords Plus® by ISI®
Normal men, Factor-i, Secretagogue, Receptor, Hexarelin, Pituitary, Insulin, Intranasal, Prolactin, Efficacy.
Abstract
After repeated intravenous (i.v.) boluses of growth hormone-releasing peptide-6 (GHRP-6) we found recently increases of growth hormone (GH), corticotropin (ACTH) and cortisol levels and of the amount of stage 2 sleep, In clinical use, oral (p.o.), intranasal (i.n.) and sublingual (s.l.) routes of administration have advantages over i.v. administration, We compared the sleep-endocrine effects of 300 mu g/kg of body weight (b.w.) GHRP-6 in enteric-coated capsules given p.o. at 21.00 h and of 30 mu g/kg GHRP-6 i.n. or 30 mu g/kg GHRP-6 st. given at 22.45 h in normal young male controls with placebo conditions. After GHRP-6 p.o. secretion of GH, ACTH and cortisol remained unchanged. The only effect of GHRP-6 s.l. was a trend toward an increase in GH in the first half of the night. GHRP-6 i.n. prompted a significant increase in GH concentration during the total night and a trend toward an increase in ACTH secretion during the first half of the night, whereas cortisol secretion remained unchanged. Furthermore, after GHRP-6 i.n., sleep stage 2 increased in the second half of the night by trend, and spectral analysis of total night non-rapid eye movement (REM) sleep revealed a decrease of delta power by trend. In contrast sleep stage 2 decreased during the second half of the night after GHRP-6 p.o. Our data demonstrate that GHRP-6 is capable of modulating GH and ACTH secretion as well as sleep. However, the effects depend upon dosage, duration and route of administration. [References: 41]
_____________________________________________
AU - Liu Q ; Lei T ; Adams EF ; Buchfedlder M ; Fahlbusch R
TI - Relationship between GHRP-6 and TPA in the regulation of growth hormone secretion by human pituitary somatotrophinomas.
SO - J Tongji Med Univ 1997;17(3):132-5
AD - Department of Pediatrics, Xiehe Hospital, Tongji Medical University, Wuhan.
Growth hormone releasing peptide (GHRP-6) is a synthetic hexapeptide which specifically stimulates secretion of growth hormone (GH) by pituitary somatotrophs. Phorbel ester, 1, 2 tetradecanoylphorbol 13 acetate (TPA) can also stimulate releasing of GH. The precise intracellular mechanism has not been entirely deciphered. We used cell cultures of human pituitary somatotrophinomas to investigate the relation between GHRP-6 and TPA on membrane phosphatidylinositol (PI) turnover and GH secretion. The results showed that the working mechanisms of GHRP-6 and TPA are not identical, although they all can stimulate GH secretion in human pituitary somatotrophinomas. This indicates that PI-PKC signal transduction system may play a crucial role in the regulation of GH secretion.
_____________________________________________
Kato M, Sakuma Y: The effect of GHRP-6 on the intracellular Na+ concentration of rat pituitary cells in primary culture. Journal of Neuroendocrinology 11:795-800, 1999.
Abstract
The objective of the present study was to further investigate the ionic mechanism of the action of GHRP-6 on male rat pituitary cells in culture. A synthetic hexapeptide, GHRP-6 stimulates the secretion of growth hormone both in vivo and in vitro. It is generally accepted that Ca2+ and protein kinase C but not cAMP are involved in the signal transduction pathway of the action of GHRP-6. Ca2+-influx through voltage-gated Ca2+ channels and mobilization of internal stored Ca2+ are thought to be responsible for an increase in cytosolic Ca2+ concentration. For activation of the voltage-gated Ca2+ channels, however, it is not determined whether the membrane Na+ permeability plays a role. To answer this question, we measured intracellular Na+ concentration of the pituitary cells with ion imaging technique. We found that GHRP-6 increased [Na+]i; the Na+ response depended on the presence of extracellular Na+ and was blocked by Gd3+, known as a blocker of nonselective cation channels but not by tetrodotoxin, a blocker of the voltage-gated Na+ channel; thapsigargin, an inhibitor of endoplasmic reticulum Ca2+ ATPase, had no effect on the response; Ca2+ chelating agent, BAPTA had no inhibitory effect on the response; ouabain, an inhibitor of Na+-K+ ATPase, did not block the rise in [Na+]i induced by GHRP-6; somatostatin, which hyperpolarizes the cells by activating K+ channels, suppressed the response. These data clearly showed that GHRP-6 increased [Na+]i in the rat pituitary cells including somatotrophs. The rise in [Na+]i is likely to be due to an increase in the membrane Na+ permeability which should depolarize the cells, thereby activating the voltage-gated Ca2+ channels. This process leads to an influx of Ca2+ and subsequent increase in [Ca2+]i which results in an exocytotic release of GH.
_____________________________________________
A complex interrelationship exists between sleep and somatotropic activity. In humans, intravenous injections of growth hormone -releasing hormone (GHRH) given during sleep consistently stimulate slow-wave (SW) sleep, particularly when given in the later part of the night. In the present study, the possible somnogenic effects induced in similar conditions by GH-releasing peptide (GHRP) were investigated in seven young healthy men. Bolus intravenous injections of GHRP-2 (1[mu]g/kg body weight) or saline, in randomized order, were given after 60 sec of the third rapid-eye-movement (REM) period. All GHRP injections were immediately followed by transient prolactin elevations and by GH pulses of a magnitude within or around the upper limit of the physiological range. Except for a non significant tendency to increased amounts of wake during the first hour following the injection, no effects of GHRP-2 administration on sleep were detected. There was in particular no enhancement of SW sleep. Thus, in contrast with GHRH, late night single injections of GHRP-2, at a dosage resulting in similar GH elevations, have no stimulatory effects on SW sleep. The present data provide evidence against the involvement of the GHRP axis in human SW sleep regulation.
Received 27 August 1997; accepted in final form 28 January 1998.
APS Manuscript Number E400-7.
Article publication pending Am. J. Physiol. (Endocrinol. Metab.).
ISSN 1080-4757 Copyright 1998 The American Physiological Society.
Published in APStracts on 19 February 1998
MORE
Category 2: Real GH or related substances, but unproven, experimental, or controversial uses
1. Type of product: real GH (recombinant human somatropin)
Route SQ
Examples Protropin, Nutropin, Humatrope, Genotropin, Norditropin, Saizen
Indications
Growth failure not due to GH deficiency or the other approved categories.
Fibromyalgia, chronic fatigue.
Burns, wound healing.
Preserving lean body mass during weight loss.
Protecting muscle and bone during high dose steroid use.
Rare types of heart failure
Status Experimental
2. Type of Product real GH (recombinant human somatropin)
Route SQ
Examples Most of above brands
Indications
Enhancing muscle strength and athletic performance. Reversing physical changes of aging in older people without GH deficiency.
Status Experimental in healthy people
3. Type of product GH-releasing agents
Routes Oral, IV, SQ
Examples Hexarelin, ghrelin, GHRP-2, GHRP-6, MK-677
Indications
Growth failure, GH deficiency; other conditions for which GH-type effects might be beneficial
Status Investigational
4. Type of product IGF-1
Route SQ
Indications
Certain GH-resistant types of growth failure
As an insulin adjunct in diabetes
Status Investigational
5. Type of product IGF1/IGFBP3
Route SQ
Status Investigational
_____________________________________________
Category 3: Products not to be confused with real GH
1. Type of product
Amino acids or protein sold as "Precursors"
Routes Oral pills, drops, sprays
Why it isn't GH
As explained above, amino acids are the building blocks of all the proteins in the body. A tiny fraction (about 1 amino acid of every 100,000 molecules) you eat will be incorporated into GH. For people getting plenty of dietary protein, eating a few more grams or even ounces of protein a day will NOT measurably increase the amount of GH you make.
2. Type of product
Amino acids or protein sold as "growth hormone releasers"
Routes Oral pills, drops, sprays
Why it isn't GH
A meal of protein without accompanying carbohydrates will often stimulate the pituitary gland to release GH, raising a person's GH levels for a few minutes. The effect is too transient to be successfully used to treat GH deficiency. I promise you that the peptide GH releasers being researched by pharmaceutical laboratories will NOT be marketed as oral dietary supplements by mall vitamin stores or MLM schemes.
3. Type of product
Homeopathic growth hormone
Route oral, nasal, pills, liquid, SQ
Why it isn't GH
The 20X or 50C homeopathic medicines are truly the emperor's new clothes of alternative medicine. If you think that even one GH receptor in your body is going to see a functional GH molecule from these products, you shouldn't be allowed to put things in your mouth without supervision.
4. Type of product
Herbal preparations
Routes Any
Why is isn't GH
Herbal means anything, but usually it means this company did not have enough confidence in its product to subject it to either (1) the research trials which would prove that it will act like GH, or (2) the FDA standards that give you the best assurance that the product contains what the label says. Remember, the sellers know more about what's in it than you do.
5. Type of product
IGF-1
Route Drops, pills, sprays
Why it isn't GH
Whatever this is, if it isn't an expensive injection obtained in an FDA-approved research protocol, it does not contain enough real and usable insulin-like growth factor 1 to provide any measurable benefit to your body.
6. Type of product
Counterfeits
Route SQ
Why it isn't GH
Apparently there are vials of something with counterfeit GH labels being sold on the internet, or in Mexican pharmacies.
GHRP was discovered by Bowers (Tulane University) 20 years ago. They act on different receptors than GH releasing hormone (GHRH) and is active orally - tho bioavailability varies from less than 1% to 50% dep on admin.
Basically teh stuff works - saw somewhere that it upped GH production by 5x in rats. Looks like snorting it might be best tho - IP's stuff is sublingual, still good IMHO.
What I would like to see is a study of the effects of GHRP and GHB (to induce REM sleep) together!!!!
Authors
Frieboes RM, Murck H, Antonijevic IA, Steiger A.
Title
Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: Role of routes of administration
Source
Journal of Neuroendocrinology. 11(6):473-478, 1999 Jun.
Author Keywords
Growth hormone, Growth hormone-releasing peptides, Corticotropins, Clinical neuroendocrinology, Sleep.
KeyWords Plus® by ISI®
Normal men, Factor-i, Secretagogue, Receptor, Hexarelin, Pituitary, Insulin, Intranasal, Prolactin, Efficacy.
Abstract
After repeated intravenous (i.v.) boluses of growth hormone-releasing peptide-6 (GHRP-6) we found recently increases of growth hormone (GH), corticotropin (ACTH) and cortisol levels and of the amount of stage 2 sleep, In clinical use, oral (p.o.), intranasal (i.n.) and sublingual (s.l.) routes of administration have advantages over i.v. administration, We compared the sleep-endocrine effects of 300 mu g/kg of body weight (b.w.) GHRP-6 in enteric-coated capsules given p.o. at 21.00 h and of 30 mu g/kg GHRP-6 i.n. or 30 mu g/kg GHRP-6 st. given at 22.45 h in normal young male controls with placebo conditions. After GHRP-6 p.o. secretion of GH, ACTH and cortisol remained unchanged. The only effect of GHRP-6 s.l. was a trend toward an increase in GH in the first half of the night. GHRP-6 i.n. prompted a significant increase in GH concentration during the total night and a trend toward an increase in ACTH secretion during the first half of the night, whereas cortisol secretion remained unchanged. Furthermore, after GHRP-6 i.n., sleep stage 2 increased in the second half of the night by trend, and spectral analysis of total night non-rapid eye movement (REM) sleep revealed a decrease of delta power by trend. In contrast sleep stage 2 decreased during the second half of the night after GHRP-6 p.o. Our data demonstrate that GHRP-6 is capable of modulating GH and ACTH secretion as well as sleep. However, the effects depend upon dosage, duration and route of administration. [References: 41]
_____________________________________________
AU - Liu Q ; Lei T ; Adams EF ; Buchfedlder M ; Fahlbusch R
TI - Relationship between GHRP-6 and TPA in the regulation of growth hormone secretion by human pituitary somatotrophinomas.
SO - J Tongji Med Univ 1997;17(3):132-5
AD - Department of Pediatrics, Xiehe Hospital, Tongji Medical University, Wuhan.
Growth hormone releasing peptide (GHRP-6) is a synthetic hexapeptide which specifically stimulates secretion of growth hormone (GH) by pituitary somatotrophs. Phorbel ester, 1, 2 tetradecanoylphorbol 13 acetate (TPA) can also stimulate releasing of GH. The precise intracellular mechanism has not been entirely deciphered. We used cell cultures of human pituitary somatotrophinomas to investigate the relation between GHRP-6 and TPA on membrane phosphatidylinositol (PI) turnover and GH secretion. The results showed that the working mechanisms of GHRP-6 and TPA are not identical, although they all can stimulate GH secretion in human pituitary somatotrophinomas. This indicates that PI-PKC signal transduction system may play a crucial role in the regulation of GH secretion.
_____________________________________________
Kato M, Sakuma Y: The effect of GHRP-6 on the intracellular Na+ concentration of rat pituitary cells in primary culture. Journal of Neuroendocrinology 11:795-800, 1999.
Abstract
The objective of the present study was to further investigate the ionic mechanism of the action of GHRP-6 on male rat pituitary cells in culture. A synthetic hexapeptide, GHRP-6 stimulates the secretion of growth hormone both in vivo and in vitro. It is generally accepted that Ca2+ and protein kinase C but not cAMP are involved in the signal transduction pathway of the action of GHRP-6. Ca2+-influx through voltage-gated Ca2+ channels and mobilization of internal stored Ca2+ are thought to be responsible for an increase in cytosolic Ca2+ concentration. For activation of the voltage-gated Ca2+ channels, however, it is not determined whether the membrane Na+ permeability plays a role. To answer this question, we measured intracellular Na+ concentration of the pituitary cells with ion imaging technique. We found that GHRP-6 increased [Na+]i; the Na+ response depended on the presence of extracellular Na+ and was blocked by Gd3+, known as a blocker of nonselective cation channels but not by tetrodotoxin, a blocker of the voltage-gated Na+ channel; thapsigargin, an inhibitor of endoplasmic reticulum Ca2+ ATPase, had no effect on the response; Ca2+ chelating agent, BAPTA had no inhibitory effect on the response; ouabain, an inhibitor of Na+-K+ ATPase, did not block the rise in [Na+]i induced by GHRP-6; somatostatin, which hyperpolarizes the cells by activating K+ channels, suppressed the response. These data clearly showed that GHRP-6 increased [Na+]i in the rat pituitary cells including somatotrophs. The rise in [Na+]i is likely to be due to an increase in the membrane Na+ permeability which should depolarize the cells, thereby activating the voltage-gated Ca2+ channels. This process leads to an influx of Ca2+ and subsequent increase in [Ca2+]i which results in an exocytotic release of GH.
_____________________________________________
A complex interrelationship exists between sleep and somatotropic activity. In humans, intravenous injections of growth hormone -releasing hormone (GHRH) given during sleep consistently stimulate slow-wave (SW) sleep, particularly when given in the later part of the night. In the present study, the possible somnogenic effects induced in similar conditions by GH-releasing peptide (GHRP) were investigated in seven young healthy men. Bolus intravenous injections of GHRP-2 (1[mu]g/kg body weight) or saline, in randomized order, were given after 60 sec of the third rapid-eye-movement (REM) period. All GHRP injections were immediately followed by transient prolactin elevations and by GH pulses of a magnitude within or around the upper limit of the physiological range. Except for a non significant tendency to increased amounts of wake during the first hour following the injection, no effects of GHRP-2 administration on sleep were detected. There was in particular no enhancement of SW sleep. Thus, in contrast with GHRH, late night single injections of GHRP-2, at a dosage resulting in similar GH elevations, have no stimulatory effects on SW sleep. The present data provide evidence against the involvement of the GHRP axis in human SW sleep regulation.
Received 27 August 1997; accepted in final form 28 January 1998.
APS Manuscript Number E400-7.
Article publication pending Am. J. Physiol. (Endocrinol. Metab.).
ISSN 1080-4757 Copyright 1998 The American Physiological Society.
Published in APStracts on 19 February 1998
MORE
Category 2: Real GH or related substances, but unproven, experimental, or controversial uses
1. Type of product: real GH (recombinant human somatropin)
Route SQ
Examples Protropin, Nutropin, Humatrope, Genotropin, Norditropin, Saizen
Indications
Growth failure not due to GH deficiency or the other approved categories.
Fibromyalgia, chronic fatigue.
Burns, wound healing.
Preserving lean body mass during weight loss.
Protecting muscle and bone during high dose steroid use.
Rare types of heart failure
Status Experimental
2. Type of Product real GH (recombinant human somatropin)
Route SQ
Examples Most of above brands
Indications
Enhancing muscle strength and athletic performance. Reversing physical changes of aging in older people without GH deficiency.
Status Experimental in healthy people
3. Type of product GH-releasing agents
Routes Oral, IV, SQ
Examples Hexarelin, ghrelin, GHRP-2, GHRP-6, MK-677
Indications
Growth failure, GH deficiency; other conditions for which GH-type effects might be beneficial
Status Investigational
4. Type of product IGF-1
Route SQ
Indications
Certain GH-resistant types of growth failure
As an insulin adjunct in diabetes
Status Investigational
5. Type of product IGF1/IGFBP3
Route SQ
Status Investigational
_____________________________________________
Category 3: Products not to be confused with real GH
1. Type of product
Amino acids or protein sold as "Precursors"
Routes Oral pills, drops, sprays
Why it isn't GH
As explained above, amino acids are the building blocks of all the proteins in the body. A tiny fraction (about 1 amino acid of every 100,000 molecules) you eat will be incorporated into GH. For people getting plenty of dietary protein, eating a few more grams or even ounces of protein a day will NOT measurably increase the amount of GH you make.
2. Type of product
Amino acids or protein sold as "growth hormone releasers"
Routes Oral pills, drops, sprays
Why it isn't GH
A meal of protein without accompanying carbohydrates will often stimulate the pituitary gland to release GH, raising a person's GH levels for a few minutes. The effect is too transient to be successfully used to treat GH deficiency. I promise you that the peptide GH releasers being researched by pharmaceutical laboratories will NOT be marketed as oral dietary supplements by mall vitamin stores or MLM schemes.
3. Type of product
Homeopathic growth hormone
Route oral, nasal, pills, liquid, SQ
Why it isn't GH
The 20X or 50C homeopathic medicines are truly the emperor's new clothes of alternative medicine. If you think that even one GH receptor in your body is going to see a functional GH molecule from these products, you shouldn't be allowed to put things in your mouth without supervision.
4. Type of product
Herbal preparations
Routes Any
Why is isn't GH
Herbal means anything, but usually it means this company did not have enough confidence in its product to subject it to either (1) the research trials which would prove that it will act like GH, or (2) the FDA standards that give you the best assurance that the product contains what the label says. Remember, the sellers know more about what's in it than you do.
5. Type of product
IGF-1
Route Drops, pills, sprays
Why it isn't GH
Whatever this is, if it isn't an expensive injection obtained in an FDA-approved research protocol, it does not contain enough real and usable insulin-like growth factor 1 to provide any measurable benefit to your body.
6. Type of product
Counterfeits
Route SQ
Why it isn't GH
Apparently there are vials of something with counterfeit GH labels being sold on the internet, or in Mexican pharmacies.
The Man Child
New member
bump
A
Adaptek
Guest
Some good posts. I think this stuff may have some benefits if its raises GH levels and keeps them constant.
